The PLLA HA Collagen Stimulator is categorized within the aesthetic market as a hybrid biostimulatory injectable. It bridges the functional gap between immediate-effect HA fillers and purely progressive, long-term PLLA suspensions.
Immediate Phase: The HA component provides initial hydration, viscoelastic support, and immediate contour correction upon injection.
Progressive Phase: The PLLA microparticles act as a biostimulatory matrix, undergoing gradual degradation while stimulating fibroblast proliferation and neocollagenesis.
Supplementary Product Parameters
|
Parameter Item |
Technical Specifications & Metrics |
|
Generic Product Name |
PLLA-HA Composite Collagen Stimulator (PLLA HA Collagen Stimulator) |
|
Main Ingredients |
Micro-crosslinked Sodium Hyaluronate (HA) + Poly-L-Lactic Acid (PLLA) Microspheres |
|
Carrier Medium / Gel Matrix |
Sodium Carboxymethyl Cellulose (CMC) / Mannitol composite suspension system (prevents microsphere sedimentation and aggregation) |
|
PLLA Microsphere Particle Size |
30 - 63 micrometers (average particle size approx. 45 micrometers, effectively avoiding granuloma risks) |
|
HA Molecular Weight & Concentration |
High molecular weight HA, concentration range 20mg/ml - 28mg/ml (customizable upon request) |
|
Packaging Specifications |
Lyophilized microsphere powder + diluent dual-chamber syringe / pre-filled sterile gel formulation |
|
Recommended Injection Plane |
Deep dermis, supraperiosteal subcutaneous injection (strictly prohibited for intravascular and superficial dermal injection) |
|
Shelf Life |
24 months to 36 months (depending on terminal sterilization method and packaging) |
|
Storage Conditions |
2°C - 30°C protected from light; freezing is strictly prohibited |
Particle Characteristics and Performance
For particulate-based injectables, particle engineering directly dictates clinical performance and safety profiles.
Variation in particle size, sphericity, and distribution can alter:
- Reconstitution behavior and suspension uniformity
- Injection force and extrusion consistency
- Tissue integration and local distribution
- Macrophage response and collagen synthesis rate
Standardized manufacturing controls ensure batch-to-batch consistency regarding particle morphology and size distribution, minimizing agglomeration risks.
Manufacturing and Quality Control Infrastructure
Production of composite polymer-hydrogel injectables requires stringent environmental controls and multi-stage verification:
Raw Material Qualification: Incoming PLLA and HA raw materials undergo rigorous testing for chemical purity, molecular weight distribution, endotoxin limits, and bioburden.
Microsphere Processing: PLLA particle synthesis is executed under controlled parameters to ensure precise size distribution and smooth surface morphology.
Formulation Homogenization: The polymer and hydrogel phases are compounded under sterile, temperature-controlled conditions to achieve uniform distribution and prevent premature degradation.
Primary Container Filling: Filling operations utilize automated, high-precision equipment housed within cleanroom environments to guarantee fill-weight accuracy and container closure integrity.
Sterilization and Release: Finished units undergo terminal sterilization using validated parameters, followed by release testing against established physical, chemical, and microbiological specifications.
Application Positioning
The product is structurally positioned for aesthetic protocols addressing:
Structural Volume Deficits: Mid-face contouring, cheek augmentation, and structural support restoration, where indicated by local regulatory approvals.
Collagen Depletion and Skin Quality: Treatment regimens focused on improving dermal thickness, structural firmness, and tissue density over successive sessions.
Quality Control Standards
Lot release testing protocols for injectable medical devices typically encompass:
Identification and Assay: Verification of PLLA and HA active concentrations.
Physicochemical Testing: pH measurement, osmolality, and rheological profiling.
Physical Properties: Particle size distribution and suspension stability.
Microbiological Safety: Sterility testing and bacterial endotoxin quantification (Limulus Amebocyte Lysate assay).
Container Integrity: Leak testing and seal strength verification.
Stability Testing: Real-time and accelerated stability programs establishing shelf-life parameters.
Manufacturing Capabilities & Facility Standards
Production is supported by dedicated medical biomaterial infrastructure:
Certified cleanroom manufacturing environments
Automated precision filling systems
Terminal sterilization and analytical testing laboratories
Purified water and Water-for-Injection (WFI) generation systems
Established quality management systems compliant with international medical device standards
OEM, ODM, and Private Label Services
Custom development options are structured to support brand owners and regional distributors:
Formulation Customization: Tailoring PLLA concentration, HA molecular weight, and particle size distribution within validated boundaries.
Packaging and Presentation: Custom primary container selection, secondary carton design, multi-language labeling, and localized IFU development.
Regulatory Documentation Support: Provision of technical files, test reports, and quality system certificates to facilitate local registration pathways.
FAQ
Q: What is a PLLA HA collagen stimulator?
A: It is an injectable medical device combining hyaluronic acid for immediate hydration and soft-tissue support with poly-L-lactic acid microparticles designed to stimulate progressive collagen production.
Q: How does it differ from a standard HA dermal filler?
A: While standard HA fillers rely entirely on cross-linked hyaluronic acid for temporary volume, a PLLA HA formulation adds a permanent or semi-permanent polymer phase that triggers long-term tissue remodeling as the material degrades.
Q: Does the product require reconstitution before use?
A: Preparation requirements depend on the final product presentation format. [Confirm whether the product is supplied as a pre-mixed formulation or requires reconstitution prior to administration].
Q: What particle size specifications are maintained for the PLLA component?
A: The PLLA particle size distribution is controlled within a validated micron range to optimize extrusion force, tissue distribution, and macrophage response. [Insert specific numerical range].
Q: What primary packaging options are available for OEM partners?
A: OEM configurations include sterile glass vials or pre-filled syringes, paired with customized secondary packaging and labeling according to target market regulations.
Q: What documentation is provided for regulatory submissions?
A: Technical dossiers, biocompatibility summaries, manufacturing process descriptions, and quality certificates are available to support regional distributor registration processes.
Hot Tags: plla ha collagen stimulator, China plla ha collagen stimulator manufacturers, suppliers, factory
